Brainsway (NASDAQ:BWAY) Given New $18.00 Price Target at HC Wainwright

Brainsway (NASDAQ:BWAY) had its price target increased by analysts at HC Wainwright from $17.00 to $18.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 12.25% from the company’s previous close.

Other research analysts have also recently issued research reports about the company. Northland Securities increased their price objective on Brainsway from $19.00 to $23.00 and gave the stock an “outperform” rating in a research note on Wednesday. Wall Street Zen raised shares of Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 17th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Brainsway in a report on Tuesday. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $20.50.

Brainsway Trading Up 1.6%

BWAY traded up $0.26 during trading hours on Thursday, hitting $16.04. The company’s stock had a trading volume of 67,079 shares, compared to its average volume of 58,655. Brainsway has a 12 month low of $7.84 and a 12 month high of $17.92. The business’s 50-day moving average price is $15.82 and its 200-day moving average price is $13.20. The stock has a market cap of $304.67 million, a price-to-earnings ratio of 53.45 and a beta of 1.22.

Brainsway (NASDAQ:BWAY) last issued its quarterly earnings data on Tuesday, November 11th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.03). The company had revenue of $13.51 million for the quarter, compared to analysts’ expectations of $13.04 million. Brainsway had a net margin of 12.73% and a return on equity of 9.65%. Brainsway has set its FY 2025 guidance at EPS. On average, analysts forecast that Brainsway will post 0.08 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BWAY. Raymond James Financial Inc. purchased a new stake in shares of Brainsway during the 2nd quarter worth $85,000. Trexquant Investment LP acquired a new position in Brainsway in the first quarter valued at approximately $129,000. NewEdge Advisors LLC increased its stake in Brainsway by 61.5% in the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock valued at $188,000 after purchasing an additional 7,549 shares during the last quarter. Y.D. More Investments Ltd acquired a new position in shares of Brainsway in the 3rd quarter valued at $263,000. Finally, Eagle Global Advisors LLC purchased a new position in shares of Brainsway in the 1st quarter valued at $590,000. Institutional investors and hedge funds own 30.11% of the company’s stock.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.